ANTX

AN2 Therapeutics, Inc.

5.90 USD

Last updated Sep 4, 20:28 UTC

Yesterday HIGH

$6.12

Yesterday LOW

$5.79

52w HIGH

$7.19

52w LOW

$1

EPS

-0.18

PE

-32.78

Next Earnings

Nov 11, 2026

Overview News Insider Transactions Government Trades Fundamentals

AN2 Therapeutics, Inc. stock is up 1.03% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 4 September’s closed higher than August.

Benzinga Newsdesk

Mon Jul 20, 2026

Guggenheim Initiates Coverage On AN2 Therapeutics with Buy Rating, Announces Price Target of $9

Guggenheim analyst Brad Canino initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Buy rating and announces Price Target of $9.
Benzinga Insights

Wed Jun 24, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-market session. The company's market cap stands at $22.1 million. Catheter Precision (AMEX:VTAK) shares rose 44.56% to
Benzinga Newsdesk

Thu Jun 4, 2026

AN2 Therapeutics Announces Results From Two Studies Evaluating Its Oral CPSF3 Inhibitor, AN2-502998, For The Treatment Of Chronic Chagas Disease; Parasites Eliminated With 28-Day Treatment In 100% Of Nonhuman Primates

AN2 Therapeutics, Inc. (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies
Benzinga Newsdesk

Thu Jun 4, 2026

AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. Cruzi

Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humansPhase 1 First-In-Human (FIH) study showed
Benzinga Newsdesk

Thu May 14, 2026

Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target

Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform and announces $9 price target.
Benzinga Newsdesk

Mon May 11, 2026

AN2 Therapeutics Q1 EPS $(0.29) Misses $(0.23) Estimate
Benzinga Newsdesk

Mon Apr 20, 2026

AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies Dated April 9, 2026; Co. May Offer And Sell Common Stock Up To $80M Through Jefferies

-SEC Filing
Benzinga Insights

Fri Apr 17, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Newsdesk

Thu Apr 9, 2026

AN2 Therapeutics Files Prospectus To Offer And Sell Up To $300M Of Securities

-SEC Filing
Benzinga Newsdesk

Thu Apr 9, 2026

AN2 Therapeutics Enters Open Market Sale Agreement With Jefferies; Co. May Issue And Sell From Time To Time Up To An Aggregate Of $80M Of Shares Of The Company's Common Stock

-SEC Filing

Margaret M FitzPatrick, Insider

Tue Sep 1, 2026

ANTX Recent Insider Trades and Stock Chart

2,098 shares bought
Robin Shane Readnour, Insider

Mon Aug 17, 2026

ANTX Recent Insider Trades and Stock Chart

35,402 shares sold
Joseph S Zakrzewski, Insider

Fri Aug 14, 2026

ANTX Recent Insider Trades and Stock Chart

405,880 shares gifted